How AI helps scientists design the next generation of medicines
MIT Technology Review AI MIT Technology Review Insights
Pharmaceutical companies like AstraZeneca are deploying AI to accelerate drug design by computationally generating and prioritizing protein candidates, then testing only the most promising ones in the lab. The company estimates AI combined with computational tools could cut drug discovery timelines by as much as 50%. This shifts drug development toward faster iteration cycles and eventually toward fully AI-designed biologics that begin as entirely new protein sequences optimized computationally before any lab testing.
Why it matters
Designing and developing a new medicine is an expensive, failure-prone scientific challenge. A new drug can take many years to develop, at the cost of a significant investment. And even then, most possible candidates never reach the patient. For biologic medicines, therapies made from engineered proteins rather than synthetic chemistry (which are often used to…
